ClinicalTrials.gg
Active, not recruitingNCT05971251Updated Oct 20, 2026

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

A Phase 1 interventional study of Loncastuximab Tesirine and Acalabrutinib in Chronic Lymphocytic Leukemia, sponsored by University of Alabama at Birmingham. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Alabama at Birmingham · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
31st of 39
24 · median 61
Started
2023
with 3 others
Phase 1
2 of 39
1 open now
Primary completion
2026-12
later than 11 of 27 live
Registered
32nd of 39
by date

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 31st largest by planned enrollment, is one of 4 that started in 2023, is one of 2 in phase 1, reaches primary completion later than 11 of the 27 other live ones, and was the 32nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.

Read the detailed description

The study is a phase I study which will employ the Bayesian optimal interval (BOIN) design to find the maximum tolerated dose (MTD).

Approximately 24 Dose-Limiting Toxicity (DLT) evaluable participants will be treated to find MTD with a target DLT rate of 25%, and 4 pre-specified doses. The total number of participants enrolled will depend on the frequency of DLTs and when the MTD is determined. The maximum number of patients at a given dose level is 12.

The dose of acalabrutinib will be fixed and loncastuximab tesirine will be titrated as in dose level table 1 below.

Table 1. Dose levels Dose Level Schedule

  1. 45 µg/kg Loncastuximab Tesirine + Acalabrutinib 100 mg BID
  2. 60 µg/kg Loncastuximab Tesirine + Acalabrutinib 100 mg BID
  3. 75 µg/kg Loncastuximab Tesirine + Acalabrutinib 100 mg BID
  4. 90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent cycles) + Acalabrutinib 100 mg BID

The DLT evaluation period is two cycles (42 days).

Loncastuximab Tesirine will be given as an IV infusion, each cycle is a 21 day cycle, with Loncastuximab Tesirine given day 1 of each cycle.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

- Inclusion Criteria For all patients

  1. Diagnosis of CLL according to the IwCLL criteria or SLL according to the World Health Organization (WHO) criteria. This includes previous documentation of:

    • -proven small lymphocytic lymphoma OR
    • Diagnosis of CLL according to the IWCLL criteria as evidenced by Peripheral blood lymphocyte count of greater than 5 x109/L .
    • Immunophenotype consistent with CLL defined as the predominant population of lymphocytes share both B cell antigens (CD19, CD20 (typically dim expression), or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc).
  2. On therapy with acalabrutinib for a minimum of 3 months without evidence of progression as per IWCLL 2018 criteria.
  3. CLL who have received at least one prior therapy before initiation of acalabrutinib
  4. Presence of measurable residual disease in the peripheral blood or bone marrow aspirate by NGS based clonoseq test.
  5. Adequate organ function as defined below unless attributed to disease involvement:

    • Liver function ( ≤ 1.5 × , and/or ALT \<3 x ULN). Patients with Gilbert Disease are permitted irrespective of bilirubin values.
    • Kidney function (crcl > 30ml/min using Cockroft-Gault, based on actual weight).
    • ≥ 1,000/µL, > 8, Count ≥ 50,000/ µL. Use of G-CSF is not permitted for up to 7 days prior to enrollment.

Exclusion Criteria:

  • Exclusion Criteria For all patients

    1. Current evidence of central nervous system involvement.
    2. Unable to generate clonoseq ID specimen for measurable residual disease tracking.
    3. Completion of an hematopoietic stem cell transplantation within 3 months prior to first dose of study drug.
    4. Prior allogeneic stem cell transplant within 6 months. The patient should not have any active Graft vs. Host disease (GVH) or should be on immune suppressive agents.
    5. Completion of treatment with any radiotherapy, chemotherapy, antibody, immunoconjugates and/or another drug ≤4 weeks (or 5 half-lives of the drug, whichever is shorter) prior to the first dose of study drug. Patients may be enrolled after a minimum of 2 weeks of radiation if radiation was for palliative intent.
    6. Progression of disease on BTK inhibitor.
    7. Unable to tolerate full dose of acalabrutinib at 100 mg twice a day.
    8. Inability to swallow and retain oral medications.
    9. Pregnant women are excluded from this study.
    10. Any active, concurrent, significant illness or disease (other underlying lymphoma) or findings including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the patient from participation in the study such as:

      • active infection requiring systemic therapy ≤10 days before the first dose of study drug
      • unstable angina pectoris, symptomatic congestive heart failure ( [NYHA] II, III, IV;), myocardial infarction ≤6 months prior to first study drug, uncontrolled cardiac arrhythmia e.g., atrial fibrillation/flutter, cerebrovascular accidents ≤6 months before first dose of study drug
      • Significant (as defined by study doctor) pulmonary disease or disorder
      • any severe or uncontrolled other disease or condition which might increase the risk associated with study participation
    11. Vaccination with live, attenuated vaccines within 28 days prior to the first dose of study medication.
    12. Receiving systemic medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents). The use of inhaled is permitted.
    13. Corticosteroids ≥ 10 mg of prednisone within the last 7 days.
    14. Has had a solid organ transplant within the last 3 years. Note: Patients who have had a Solid organ transplant >3 years ago are eligible if there are no signs/symptoms of (GvHD) and off immunosuppressive medications as per above.
    15. Known history of to loncastuximab tesirine
    16. Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
    17. Breastfeeding or pregnant
    18. Any other known to be active, with the exception of

      • Cervical carcinoma of Stage 1A (1A1,1A2) and 1B (1B1,1B2,1B3)
      • Non-invasive basal cell or squamous cell skin carcinoma
      • Non-invasive, superficial bladder cancer
      • Prostate cancer with a current PSA level \< 0.1 ng/mL
      • Any curable or localized cancer with a CR of > 2 years' duration.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Dose Level 1:

    45 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles

    Drug: Loncastuximab Tesirine and Acalabrutinib

  • Experimental
    Dose Level 2

    60 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles

    Drug: Loncastuximab Tesirine and Acalabrutinib

  • Experimental
    Dose Level 3

    75 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles

    Drug: Loncastuximab Tesirine and Acalabrutinib

  • Experimental
    Dose level 4:

    90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent 10 cycles) + Acalabrutinib 100 mg BID for a total of 12 cycles.

    Drug: Loncastuximab Tesirine and Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Objective

    Recommended phase 2 dose of loncastuximab tesirine in combination with acalabrutinib

    Time frame: 12 months

Secondary outcomes

  1. Secondary Objective 1

    undetectable measurable residual disease rate (uMRD) at 6 months of combination therapy in peripheral blood by NGS based clonoseq test

    Time frame: 6 months

  2. Secondary Objective 2

    Undetectable measurable residual disease rate (uMRD) at 12 months of combination therapy by NGS based clonoseq test.

    Time frame: 12 months

  3. Secondary Objective 3

    Best Overall response rate (ORR = CR+CRi+PR) of loncastuximab tesirine in combination with acalabrutinib

    Time frame: 12 months

  4. Secondary Objective 4

    Complete response rate (CRR= CR + CRi) of loncastuximab tesirine in combination with acalabrutinib in achieving a complete response.

    Time frame: 12 months

  5. Secondary Objective 5

    Progression free survival (PFS) at 12 months after completion of all treatment.

    Time frame: 12 months

  6. Secondary Objective 6

    Incidence of adverse events (AE) of loncastuximab tesirine in combination with acalabrutinib.

    Time frame: 12 months

  7. Secondary Objective 7

    Duration of response (DOR) of loncastuximab tesirine in combination with acalabrutinib

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 96 non-industry phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 91. This study's planned 36 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Aug 2, 2023
StartActual
Dec 18, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05971251
Collaborators
ADC Therapeutics S.A.
Responsible party
Aditi Saha, MD (Assistant Professor, Department of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 2, 2023
Start date
Dec 18, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Aditi Saha, M.D.
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Loncastuximab tesirine · Acalabrutinib

Start the discussion